Gene Expression Signature Predicts Immune-Related Adverse Events in Melanoma Patients

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 12, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, Aug. 12, 2024 -- A gene expression signature in peripheral CD4⁺ T-cells can predict severe immune-related adverse events (irAEs) among melanoma patients treated with ipilimumab/nivolumab, according to a study published online Aug. 8 in Clinical Cancer Research.

Kelsey R. Monson, Ph.D., from the Perlmutter Cancer Center at NYU Langone Health in New York City, and colleagues examined postsurgical, pre-immune checkpoint inhibitor treatment peripheral CD4⁺ and CD8⁺ T-cells from melanoma patients in a clinical trial (CheckMate-915) treated with adjuvant nivolumab (130 patients) or ipilimumab/nivolumab (COMBO; 82 patients). Baseline differences associated with severe (grade 3 to 5) irAEs were tested and a predictive model was constructed.

The researchers found significant enrichment of the spleen tyrosine kinase (SYK) pathway in peripheral CD4⁺ cells, which was associated with severe irAEs in COMBO-treated patients. Severe irAE COMBO patients were predicted by this gene-expression signature with 73 percent accuracy, independent of disease recurrence. The irAE predictive model that incorporated this gene-expression signature had 82 percent accuracy.

"Predictive information of this kind is critically important to oncologists and patients to help guide their immunotherapy decisions, to either minimize these side effects by taking additional precautions or choose alternative immunotherapies," Monson said in a statement.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Posted August 2024

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Recently Approved

Nuvaxovid
Nuvaxovid (COVID-19 Vaccine, Adjuvanted) is a protein-based, non-MRNA vaccine...
Emrelis
Emrelis (telisotuzumab vedotin) is a first-in-class, c-Met protein directed...
Avmapki Fakzynja Co-Pack
Avmapki Fakzynja Co-Pack (avutometinib and defactinib, co-packaged) is a kinase...

More drug approvals

Circulating Tumor DNA Can ID Outcomes for Patients With Melanoma

Common Photosensitizing Drugs Increase Skin Cancer Risk

Adding 3D Total Body Photography to Usual Care Increases Rate of Skin Excisions